Audrey Kam, MD
Hematology & Oncology · Chicago, ILNPI 1659635977
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,500 of the $1,600 with a category attached, or 93.8%. Ipsen Biopharmaceuticals, Inc accounts for 99.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 3 payments — averaging $533.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$2K
- Intuitive Surgical$12
Across 154 payments — averaging $4814.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$553K
- Boston Scientific$70K
- Exelixis Inc.$39K
- Seagen Inc.$39K
- Pfizer$29K
- Novocure Inc.$12K
What the payments were for
- Consulting fees$1,50094%
- Food & beverage$1006%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 2 | $1,588 |
| Intuitive Surgical | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATULINE DEPOT$1,500
How this compares
$1,600 in reported general payments places this provider in the 45th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 14 | $42,992 |
| Prochlorperazine Maleate | 72 | $659 |
| Ondansetron Hcl | 76 | $397 |
| Mirtazapine | 12 | $350 |
| LoperamideLoperamide Hcl | 24 | $349 |
| Dexamethasone | 15 | $293 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.